{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-095577","form_type":"8-K","ticker":"APGE","cik":"0001974640","company_name":"Apogee Therapeutics, Inc.","filed_at":"2023-08-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:36.151903+00:00","generated_at":"2026-06-11T03:09:54.476871+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Apogee Therapeutics Q2 net loss $18.9M; $345M IPO funds runway into 4Q26","bullets":["Raised $345M in upsized July IPO; cash balance $125.1M at June 30; projected runway into 4Q 2026.","Phase 1 trial of APG777 initiated; initial safety/PK data expected mid-2024.","Appointed Mark McKenna Chairman, Matt Batters General Counsel, Rebecca Dabora CTO.","Net loss Q2 2023 $18.9M vs $1.8M in Q2 2022; R&D expenses rose to $13.9M.","APG808 development candidate selected expected Q4 2023; APG990 candidate in 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-095577","json":"https://secwatch.observer/filing/0001104659-23-095577.json","markdown":"https://secwatch.observer/filing/0001104659-23-095577.md","text":"https://secwatch.observer/filing/0001104659-23-095577.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1974640/000110465923095577/0001104659-23-095577-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1974640/000110465923095577/tm2324402d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T03:09:54.476871+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"64d784037aabf27b3456ebd286d37fb106942e36","claim":"Apogee Therapeutics, Inc. reported financial results for second quarter 2023.","evidence_excerpt":"On August 28, 2023, Apogee Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended June 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1974640/000110465923095577/0001104659-23-095577-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"second quarter 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}